Gyre Therapeutics, Inc.
GYRE
$8.44
-$0.37-4.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 105.76M | 105.03M | 111.59M | 115.69M | 113.45M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 105.76M | 105.03M | 111.59M | 115.69M | 113.45M |
| Cost of Revenue | 3.88M | 3.96M | 4.18M | 4.49M | 4.64M |
| Gross Profit | 101.87M | 101.08M | 107.40M | 111.20M | 108.81M |
| SG&A Expenses | 73.62M | 77.82M | 75.38M | 77.25M | 75.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 89.53M | 94.66M | 92.68M | 95.07M | 94.24M |
| Operating Income | 16.23M | 10.38M | 18.91M | 20.62M | 19.21M |
| Income Before Tax | 23.22M | -77.83M | -70.57M | -70.76M | -76.97M |
| Income Tax Expenses | 5.32M | 5.82M | 8.42M | 9.01M | 8.52M |
| Earnings from Continuing Operations | 17.90 | -83.65 | -78.99 | -79.76 | -85.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -5.81M | -5.17M | -6.98M | -7.88M | -7.45M |
| Net Income | 12.09M | -88.82M | -85.97M | -87.65M | -92.93M |
| EBIT | 16.23M | 10.38M | 18.91M | 20.62M | 19.21M |
| EBITDA | 17.82M | 11.80M | 20.08M | 21.87M | 20.33M |
| EPS Basic | 0.14 | -1.25 | -1.20 | -1.21 | -1.27 |
| Normalized Basic EPS | 0.10 | -0.03 | 0.02 | 0.02 | -0.02 |
| EPS Diluted | 0.11 | -1.28 | -1.25 | -1.23 | -1.29 |
| Normalized Diluted EPS | 0.10 | -0.03 | 0.01 | 0.00 | -0.04 |
| Average Basic Shares Outstanding | 340.36M | 326.97M | 304.92M | 283.00M | 263.33M |
| Average Diluted Shares Outstanding | 376.18M | 362.79M | 339.06M | 313.64M | 309.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |